Those who inherit a mutant allele of the RB1 tumor-suppressor gene are at risk for developing a bone cancer called osteosarcoma. You suspect that in these cases, osteosarcoma requires a mutation in the second RB1 allele, and you have cultured some osteosarcoma cells and obtained a cDNA clone of a normal human RB1 gene. A colleague sends you a research paper revealing that a strain of cancer-prone mice develop malignant tumors when injected with osteosarcoma cells, and you obtain these mice. Using these three resources, what experiments would you perform to determine (a) whether osteosarcoma cells carry two RB1 mutations, (b) whether osteosarcoma cells produce any pRB protein, and (c) if the addition of a normal RB1 gene will change the cancer-causing potential of osteosarcoma cells?

Video transcript

Hey everyone. Let's take a look at this question. Together, patients with chronic myelogenous leukemia have a C. D. A. B. L. Gene which is trans located from chromosome nine to chromosome 22. This translocation is referred to as what So let's recall what we know about patients with CML and what happens when chromosome nine is trans located two, chromosome 22. So when we're dealing with that translocation of chromosome nine to chromosome 22 we know that we end up with a defective and short chromosome. And this is a genetic abnormality, which we call philadelphia chromosome because philadelphia chromosome refers to that specific genetic abnormality in which chromosome 22 of the leukemia cancer cells is defective and is short because of that reciprocal translocation of the material between that chromosome nine and that chromosome 22. So that makes answer choice D Phila a chromosome. The correct answer. Because we know that when we have that translocation of chromosome nine to chromosome 22 we end up with that defective and short chromosome, which is a genetic abnormality called philadelphia chromosome, which is answer choice D. The correct answer. I hope you found this video to be helpful. Thank you and goodbye